Sinem Ermin

Sinem Ermin

Auto-generated profile, based on publicly available information

Sinem Ermin

Department of Chest Diseases, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, University of Health Sciences, Izmir, Turkey

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2022 in Lung India
Verified
Journal Article
Open access
SESinem Ermin
Sinem Ermin
YÖYasemin Özdoğan
Yasemin Özdoğan
ÖBÖzgür Batum
Özgür Batum
UYUfuk Yılmaz
Ufuk Yılmaz
Background: Malignant pleural effusion (MPE) is a condition, that can be seen in 15% of patients diagnosed with cancer. Because of the short overall survival, it is important to identify the appropriate treatment. In addition to the palliation of secondary symptoms due to MPE, it should also be decided in which cases a more aggressive treatment is to be followed. The purpose of the study was to evaluate the performance of LENT and clinical PROMISE scores in predicting survival in patients with MPE Methods: Age, sex, smoking history, Eastern Cooperative Oncology Group (ECOG) score, cancer type, history of chemotherapy/radiotherapy, laboratory values, and pleural fluid lactate dehydrogenase were recorded. The LENT and the PROMISE scores were calculated and risk categories were determined. During the follow-up, blood tests and tomography controls were performed on the patients as routine. The overall survival was calculated as the period from the date of diagnosis of MPE to death or until December 31, 2019 Results: A total of 169 patients were included. The median age was 65 (26–86). In the single-variable analysis, there was a significant increase in mortality risk in the poor performance score and if the LENT risk group progressed from the low-to medium-/high-risk group or PROMISE categories A to B, A to C or A to D. In multivariate analysis, mortality risk in 1, 3, 6, and 12 months increased significantly in poor performance score, in PROMISE category B, C, and D. In high LENT risk-group, an increased mortality risk was shown in only 12 months of survival Conclusions: Our data show that poor performance score (ECOG 3-4), PROMISE category B, C, and D significantly increase mortality risk and the LENT score is inadequate in predicting survival.

14 March 2020 in The Clinical Respiratory Journal
Verified
Journal Article
Closed access
PDF file
ÖÖÖzer Özdemir
Özer Özdemir
ÖBözgür Batum
özgür Batum
SESinem Ermin
Sinem Ermin
NANimet Aksel
Nimet Aksel
BKBerna Kömürcüoğlu
Berna Kömürcüoğlu
UYUfuk Yılmaz
Ufuk Yılmaz

20 October 2018 in The Clinical Respiratory Journal
Verified
Journal Article
Closed access
PDF file
SESinem Ermin
Sinem Ermin
AÇAkın Çinkooğlu
Akın Çinkooğlu
SSSeher Susam
Seher Susam
ÖBözgür Batum
özgür Batum
UYUfuk Yılmaz
Ufuk Yılmaz

24 February 2025 in The Egyptian Journal of Bronchology
Verified
Journal Article
Open access
PDF file
DUDamla Serçe Unat
Damla Serçe Unat
ŞAŞener Arikan
Şener Arikan
ÖKÖzgür Kirbiyik
Özgür Kirbiyik
GBGünseli Balci
Günseli Balci
SESinem Ermin
Sinem Ermin
AMAydan Mertoğlu
Aydan Mertoğlu
Introduction: Brain metastasis (BM) in non-small cell lung cancer (NSCLC) is still an important reason for morbidity and mortality despite the advances in cancer treatment. Using tyrosine kinase inhibitors against epidermal growth factor receptors (EGFR) mutations revolutionized NSCLC treatment. We investigated whether the presence of EGFR mutation influences survival in patients with lung adenocarcinoma with BM. Material and methods: The data of the patients with pathological diagnoses of NSCLC and BM at tertiary hospitals were analyzed retrospectively in terms of survival. A total of 2554 patients diagnosed with NSCLC pathologically between 01 January 2010 and 01 January 2021 were identified. After the exclusion of patients with a lack of data, unknown EGFR mutation status, no brain metastasis, and additional malignancy 336 patients were included in the study. Results: It was found that EGFR ( +) patients were more female dominant (48.6% vs 13.3% p < 0.0001) and were have less history of smoking (47.2% vs 87.1%, p < 0.0001) and were better survival (79.2% vs 92.8%). We found negativity of EGFR increased death risk by 1.700 times (95% CI 1.323–2.183, p < 0.0001) in univariate analysis and by 1.724 times (95% CI 1.251–2.377, p = 0.0001) in multivariate analysis. When overall survivals were compared estimated overall survival time of EGFR ( −) patients was 10.088 (95% CI 8.571–11.606) months and of EGFR ( +) patients was 11.829 months (95% CI 10.336–13.323) (p < 0.001). Conclusion: EGFR positivity was associated with survival. Also, survival was significantly longer in EGFR-positive patients with brain metastases diagnosed with NSCLC.

5 November 2024 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
MŞMelahat Uzel Şener
Melahat Uzel Şener
PKPınar Akın Kabalak
Pınar Akın Kabalak
SKSuna Kavurgacı
Suna Kavurgacı
NDNilgün Yılmaz Demirci
Nilgün Yılmaz Demirci
DKDerya Kızılgöz
Derya Kızılgöz
ÜYÜlkü Yılmaz
Ülkü Yılmaz

30 April 2024 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
SYSüleyman Yıldırım
Süleyman Yıldırım
CKCenk Kirakli
Cenk Kirakli
YÖYeliz Özdemir
Yeliz Özdemir
STSelma Tosun
Selma Tosun
SESinem Ermin
Sinem Ermin
EIEnver İlHan
Enver İlHan
Introduction: Vaccination against coronavirus disease-19 (COVID-19) is highly effective in preventing severe disease and mortality. Adenoviral vector and mRNA vaccines were effective against intensive care unit (ICU) admission, but the effectiveness of inactivated vaccine on ICU admission was unclear. We aimed to evaluate the effect of vaccination status on ICU admission in hospitalized COVID-19 patients in a country with heterologous vaccination policy. Methodology: This is a retrospective multicenter study conducted in three hospitals in Izmir, Turkey between 1 January 2021 and 31 March 2022. Patients aged ≥ 18 years and hospitalized due to COVID-19 were included in the study. Patients who had never been vaccinated and patients who had been vaccinated with a single dose were considered unvaccinated. A logistic regression analysis was performed for evaluating risk factors for ICU admission. Results: A total of 2,110 patients were included in the final analysis. The median age was 66 years (IQR, 53-76 years) and 54% of the patients were vaccinated. During the study period, 407 patients (19.3%) were transferred to the ICU due to disease severity. Patients who were admitted to the ICU were older (median age 68 vs. 65 years, p < 0.001); and the number of unvaccinated individuals was higher among ICU patients (57% vs. 45%, p < 0.001). In multivariate regression analysis, being unvaccinated was found to be the most important independent risk factor for ICU admission with an OR of 2.06 (95% CI, 1.64-2.59). Conclusions: Vaccination against COVID-19 is effective against ICU admission and hospital mortality.